Table 4.
Patient characteristic for patients in TKV analysis by CKD stage values
| Patient characteristic | Entire population | CKD stage | |||
|---|---|---|---|---|---|
| G1 + G2 | G3a | G3b | G4 | ||
| Number of patients | n = 253 | n = 64 | n = 45 | n = 66 | n = 78 |
| Age (years) | 49.1 ± 11.4 | 40.2 ± 7.8 | 49.9 ± 10.9 | 50.0 ± 9.6 | 55.2 ± 11.2 |
| Sex (Male; %) | 49.4 | 48.4 | 46.7 | 51.5 | 50.0 |
| Height (cm) | 165.4 ± 9.3 | 165.3 ± 8.3 | 165.7 ± 10.5 | 165.5 ± 10.0 | 165.3 ± 9.1 |
| Weight (kg) | 64.3 ± 12.9 | 64.2 ± 13.3 | 63.6 ± 11.7 | 65.8 ± 14.6 | 63.8 ± 12.0 |
| Body mass index (kg/m2) | 23.4 ± 4.0 | 23.4 ± 4.0 | 22.9 ± 3.1 | 24.1 ± 5.1 | 23.2 ± 3.4 |
| Systolic blood pressure (mmHg) | 130.4 ± 15.2 | 127.1 ± 14.4 | 131.1 ± 17.5 | 134.9 ± 16.0 | 128.9 ± 12.6 |
| Diastolic blood pressure (mmHg) | 82.4 ± 11.8 | 80.8 ± 12.7 | 83.0 ± 10.7 | 85.2 ± 12.9 | 80.8 ± 10.1 |
| Blood urea nitrogen (mg/dL) | 23.0 ± 9.0 | 15.3 ± 4.1 | 18.6 ± 4.8 | 23.0 ± 5.1 | 31.8 ± 8.9 |
| Serum creatinine level (mg/dL) | 1.5 ± 0.7 | 0.8 ± 0.2 | 1.1 ± 0.2 | 1.5 ± 0.3 | 2.3 ± 0.6 |
| e-GFR (mL/min/1.73 m2) | 45.6 ± 22.5 | 77.6 ± 13.3 | 51.5 ± 3.9 | 37.1 ± 4.4 | 22.7 ± 4.4 |
| Total kidney volume (mL) | 2037 ± 1277 | 1361 ± 453 | 1856 ± 959 | 2556 ± 1851 | 2255 ± 1037 |
| Height-adjusted total kidney volume (mL/m) | 1223 ± 781 | 824 ± 268 | 1051 ± 501 | 1569 ± 1154 | 1375 ± 644 |
| Total administration period (day) | 835 ± 360 | 847 ± 345 | 922 ± 379 | 847 ± 353 | 763 ± 360 |
| Starting dose (mg) | 47.6 | 54.8 | 52.3 | 49.3 | 37.5 |
| Average daily dose (mg/day) | 66.0 | 75.7 | 74.3 | 72.8 | 47.5 |
| Daily dose (most frequent dose) (mg/day) | 67.6 | 76.2 | 74.0 | 75.9 | 50.0 |
| Daily dose (final dose) (mg/day) | 70.7 | 83.0 | 83.0 | 79.5 | 46.0 |
All values are expressed as mean ± SD, or in the case of sex as percentage of male subjects and dose as mean
Depending on patient characteristics, the patient number may differ because of missing data